title: S-Allylcysteine prevents the rat from 3-nitropropionic acid-induced hyperactivity, early markers of oxidative stress and mitochondrial dysfunction.
abstract: We investigated the effects of S-allylcysteine (SAC) on early behavioral alterations, striatal changes in superoxide dismutase (SOD) activity, lipid peroxidation (LP) and mitochondrial dysfunction induced by the systemic infusion of 3-nitropropionic acid (3-NPA) to rats. SAC (300 mg/kg, i.p.), given to animals 30 min before 3-NPA (30 mg/kg, i.p.), prevented the hyperkinetic pattern evoked by the toxin. In addition, 3-NPA alone produced decreased activities of manganese- (Mn-SOD) and copper/zinc-dependent superoxide dismutase (Cu,Zn-SOD), increased LP (evaluated as the formation of lipid fluorescent products) and produced mitochondrial dysfunction in the striatum (measured as decreased 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction). In contrast, pretreatment of 3-NPA-injected rats with SAC resulted in a significant prevention of all these markers. Our findings suggest that the protective actions of SAC are related with its antioxidant properties, which in turn may be accounting for the preservation of SOD activity and primary mitochondrial tasks.
authors.affiliation: Laboratorio de Aminoácidos Excitadores, Instituto Nacional de Neurología y Neurocirugía, México DF, Mexico.
authors.forename: María N
authors.initials: MN
authors.lastname: Herrera-Mundo
authors.forename: Daniela
authors.initials: D
authors.lastname: Silva-Adaya
authors.forename: Perla D
authors.initials: PD
authors.lastname: Maldonado
authors.forename: Sonia
authors.initials: S
authors.lastname: Galván-Arzate
authors.forename: Leticia
authors.initials: L
authors.lastname: Andrés-Martínez
authors.forename: Verónica
authors.initials: V
authors.lastname: Pérez-De La Cruz
authors.forename: José
authors.initials: J
authors.lastname: Pedraza-Chaverrí
authors.forename: Abel
authors.initials: A
authors.lastname: Santamaría
mesh_terms: D017109:Akathisia, Drug-Induced; D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism; D001522:Behavior, Animal / Q000187:drug effects; D015415:Biomarkers / Q000378:metabolism*; D003292:Convulsants / Q000494:pharmacology*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D003545:Cysteine / Q000031:analogs & derivatives* / Q000378:metabolism; D007527:Isoenzymes / Q000378:metabolism; D015227:Lipid Peroxidation; D008297:Male; D008928:Mitochondria / Q000378:metabolism*; D009574:Nitro Compounds / Q000494:pharmacology*; D018384:Oxidative Stress; D011422:Propionates / Q000494:pharmacology*; D011595:Psychomotor Agitation; D051381:Rats; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D003292:Convulsants; D007527:Isoenzymes; D009574:Nitro Compounds; D011422:Propionates; C065299:S-allylcysteine; D013482:Superoxide Dismutase; D003545:Cysteine; C015392:3-nitropropionic acid